Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis

Su, Si-Biao

doi:10.3748/wjg.v21.i14.4323

Cited by 53 publications

(40 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed that CA19.9, which has been widely investigated in pancreatic illness ( Winter et al , 2013 ), was also the most relevant marker for PA diagnosis, with a sensitivity of 79% and specificity of 93%. Two meta-analyses found similar values, with 79–81% sensitivity and 82–90% specificity ( Ballehaninna and Chamberlain, 2012 ; Su et al , 2015 ). However, the usefulness of CA19.9 for PA diagnosis is still debated because of its low specificity.…”

Section: Discussionmentioning

confidence: 74%

“…To date, the carbohydrate antigen CA19.9 (CA19.9), which has been approved by the FDA for PA management, is the only marker used in daily practice. Its clinical interest has been intensively studied, and it has a sensitivity of 70–81% for PA diagnosis ( Chan et al , 2014 ; Su et al , 2015 ). The well-known limitation of CA19.9 is its low specificity due to the presence of elevated levels in non-malignant situations, such as cholestasis or diabetes mellitus.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

et al. 2017

View full text Add to dashboard Cite

Background:The direct comparison of CA19.9, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis of solid pancreatic tumours (SPTs).Methods:We included 68 patients with a SPT referred for EUS-FNA. CTCs were analysed using size-based platform and ctDNA using digital PCR. The sensitivity, specificity, negative and positive predictive values were evaluated for each marker and their combination.Results:SPTs corresponded to 58 malignant tumours (52 pancreatic adenocarcinoma (PA) and 6 others) and 10 benign lesions. The sensitivity and specificity for PA diagnosis were 73% and 88% for EUS-FNA, 67% and 80% for CTC, 65% and 75% for ctDNA and 79% and 93% for CA19.9, respectively. The positivity of at least 2 markers was associated with a sensitivity and specificity of 78% and 91%, respectively. CtDNA was the only marker associated with overall survival (median 5.2 months for ctDNA+ vs 11.0 months for ctDNA−, P=0.01).Conclusions:CA19.9 alone and in combination with ctDNA and/or CTC analysis may represent an efficient method for diagnosing PA in patients with SPTs. Further studies including a larger cohort of patients with both malignant and benign lesions will be necessary to confirm these promising results.

show abstract

Section: Discussionmentioning

confidence: 74%

mentioning

confidence: 99%

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PC is an aggressive disease with almost no symptoms until the cancer is well established [24,25]. Carbohydrate antigen 19 − 9 is the only diagnostic marker approved by the FDA, but its diagnostic potential is limited due to its limited sensitivity and speci city [26,27]. Therefore, screening new tumor biomarkers is important for the early diagnosis and targeted treatment of PC.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance and Prognostic Value of the Expression of Fibronectin Type III Domain Containing 3B in Pancreatic Carcinoma

Ma¹,

Liao²,

Du³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pancreatic carcinoma (PC) is one of the most aggressive cancers affecting human health. Identifying candidate biomarkers is essential for the early diagnosis and good prognosis of PC. Fibronectin type III domain containing 3B (FNDC3B) promotes many types of cancer, but its role in pancreatic cancer is not clear. The purpose of this study was to investigate the relationship between the expression of FNDC3B and incidence of PC. Methods: We downloaded data related to the levels of FNDC3B mRNA in patients of PC from the Cancer Genome Atlas (TCGA) database, and conducted in-depth research on this data and its clinical significance through the R tools. We used GO and KEGG enrichment analyses to study the genes and signaling pathways that may be regulated by FNDC3B. Results: The results showed that the level of FNDC3B mRNA in PC tissues was higher than that in the normal tissues, and this was associated with proliferation and lymph node metastases of PC. Increased levels of FNDC3B mRNA also predict poor prognosis for the patients with PC. In addition, enhanced levels of FNDC3B mRNA were involved in the regulation of cell junction, tissue and epithelial cell migration, and several signal transduction pathways, including notch, TGF-β, VEGF, and Wnt. Conclusions: In short, high levels of FNDC3B mRNA may be associated with progression of PC and indicate a poor prognosis in patients with PC.

show abstract

“…Our patient demonstrated repeatedly negative biopsy by EUS. Furthermore, CA 19-9 was normal throughout the evaluation, though it is elevated in 80% of cases of pancreatic adenocarcinoma, especially cases presenting with common bile duct obstruction [ 14 , 15 ]. Our patient did not have Lewis null blood type, which does not produce CA 19-9 [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis

et al. 2017

View full text Add to dashboard Cite

Pancreatic cancer carries poor prognosis. Establishing the diagnosis early could help in improving outcome. We are presenting a case of pancreatic cancer with delayed diagnosis. Our 60-year-old patient underwent multiple endoscopic ultrasound-guided biopsies with no evidence of malignancy. He had normal molecular tumor biomarkers. The patient needed 8 months to receive the diagnosis and initiate the treatment. There are no specific guidelines regarding choice of tissue sampling modalities in such cases.

show abstract

Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis

Abstract: Elevated CA19-9 by itself is insufficient for differentiating pancreatic carcinoma and chronic pancreatitis, however, it increases suspicion of pancreatic carcinoma and may complement other clinical findings to improve diagnostic accuracy.

Cited by 53 publications

References 54 publications

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

Clinical Significance and Prognostic Value of the Expression of Fibronectin Type III Domain Containing 3B in Pancreatic Carcinoma

Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis

Contact Info

Product

Resources

About